title: Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.
abstract: OBJECTIVE
  Recurrence of hepatitis C after liver transplantation (LT) is universal and may cause premature graft loss. We evaluated the efficacy and safety of antiviral therapy in HCV-infected patients with decompensated cirrhosis awaiting LT.
  
  
  METHODS
  Fifty-one patients underwent treatment with peginterferon-alfa-2a and ribavirin. A control group of 51 untreated individuals awaiting LT were matched by age, Child-Pugh and MELD scores and time on the waiting list.
  
  
  RESULTS
  Case and control patients were comparable for all relevant variables. Fifteen treated patients (29%) had undetectable HCV-RNA at the time of transplantation and 10 (20%) achieved SVR. Early virological response and non-1 genotype were the strongest predictors of viral clearance. There was a higher incidence of bacterial infections in treated patients vs controls, particularly in Child-Pugh B-C individuals (17 vs 3 episodes) (log-rank=0.0016). Importantly, the incidence of spontaneous bacterial peritonitis (SBP) in patients who were not receiving norfloxacin prophylaxis (n=83) was significantly higher in the treated group than in controls (log-rank=0.01).
  
  
  CONCLUSIONS
  Our data demonstrate that antiviral treatment prevents hepatitis C recurrence in 20% of HCV-infected patients. However, treatment should be recommended with caution in individuals with poor liver function who do not receive norfloxacin prophylaxis for SBP, since it increases the risk of bacterial infections.
authors.affiliation: Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Ciberehd and IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Carrión
authors.forename: Eva
authors.initials: E
authors.lastname: Martínez-Bauer
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Crespo
authors.forename: Santseharay
authors.initials: S
authors.lastname: Ramírez
authors.forename: Sofia
authors.initials: S
authors.lastname: Pérez-del-Pulgar
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: García-Valdecasas
authors.forename: Miquel
authors.initials: M
authors.lastname: Navasa
authors.forename: Xavier
authors.initials: X
authors.lastname: Forns
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000453:epidemiology*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000453:epidemiology / Q000382:microbiology; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology / Q000382:microbiology; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety; D013997:Time Factors; D019562:Viral Load; D014850:Waiting Lists; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a